Global Liver Cancer Treatment Market 2025-2035

Description

List of Tables

Liver Cancer Treatment Market Size, Share & Trends Analysis Report by Cancer Type (Hepatocellular Carcinoma (HCC), Cholangiocarcinoma, Hepatoblastoma, Fibrolamellar Carcinoma, and Others) by Source (Synthetic, and Natural) and by Therapy Type (Targeted Therapy, Immunotherapy, Chemotherapy, Radiation Therapy, and Surgical Interventions) Forecast Period (2026-2035)

Industry Overview

Liver cancer treatment market was valued at $4,920 million in 2025 and is projected to reach $14,400 million by 2035, growing at a CAGR of 11.4% during the forecast period (2026-2035). The increasing incidence of liver cancer diagnoses and mortality across the world is driving the demand for effective treatments, screening, and disease management solutions, thus propelling market growth. According to the American Cancer Society Org., in 2025, approximately 42,240 individuals in the US are likely to be diagnosed with liver cancer 2025, and around 30,090 are likely to die from it. The most common types of liver cancer are hepatocellular carcinoma, which represents 70% of all cases, and intrahepatic bile duct cancer, or cholangiocarcinoma, which represents 21%. Liver cancer is almost three times more common among men than among women.

Additionally, in the US, approximately 75% of liver cancer incidence is attributed to modifiable risk factors, including obesity, hepatitis B and C virus infection, smoking, and drinking three or more alcoholic beverages a day. Other risks are type 2 diabetes, nonalcoholic fatty liver disease, and aflatoxin from contaminated food. While low-dose aspirin may lower risk, its side effects often outweigh its benefits for most individuals.

The 5-year relative survival rate for liver cancer has improved to 22%, compared to just 3% forty years ago. For patients diagnosed with localized stage disease, the 5-year survival rate is 37%.

Market Dynamics

Increased R&D Investments and Commercial Expansion

The growth of the hepatocellular carcinoma (HCC) market is largely due to augmented R&D investments and commercialization in the development, optimization, and global commercialization of next-generation treatment modalities. For instance, in August 2024, HistoSonics raised $102 million for the treatment of hepatocellular carcinoma (HCC) using a non-invasive, non-thermal technology known as histotripsy. Histotripsy is a non-invasive, non-thermal focused ultrasound technology that generates a bubble cloud to physically ablate liver tumors without thermal effects, providing a potentially superior alternative to conventional treatments with severe side effects. It intended to use Series D financing to develop its non-invasive histotripsy platforms and accelerate commercial growth in the US and international markets.

Market Segmentation

Based on the cancer type, the market is segmented into hepatocellular carcinoma (HCC), cholangiocarcinoma, hepatoblastoma, fibrolamellar carcinoma, and others (angiosarcoma of the liver)
Based on the therapy type, the market is segmented into targeted therapy, immunotherapy, chemotherapy, radiation therapy, and surgical interventions.

Hepatocellular Carcinoma (HCC): A Key Segment in Market Growth

The rise in HCC incidence and market growth is attributed to the rise in risk factors such as metabolic disorders, obesity, diabetes, and alcohol-related liver conditions. Hepatocellular carcinoma (HCC) is a major global cancer, the third leading cause of cancer-related mortality. Despite decreased cases due to universal vaccination and antiviral therapy, HCC related to metabolic dysfunction and alcohol-associated liver disease is increasing. Early detection is obtained by liver ultrasonography and serum a-fetoprotein, and other tools such as blood-based biomarker panels and MRI are under investigation. Treatment is advanced and multidisciplinary, taking into account tumor burden, liver dysfunction, and patient preferences.

According to the Korean Association for the Study of the Liver Org., in 2025, Hepatocellular carcinoma (HCC) is the most common form of liver cancer, causing nearly 90% of cases. The ongoing changes in its epidemiology significantly influence the strategies for preventing, screening, and treating HCC. These considerations are essential when evaluating new screening methods, such as blood-based biomarker panels and simplified MRI protocols, in addition to the treatment options involving immune checkpoint inhibitor combinations. This article intends to thoroughly examine the current global epidemiology and the latest evidence regarding the surveillance, diagnosis, and treatment of HCC.

Regional Outlook

The global liver cancer treatment market is further divided by region, including North America (the US and Canada), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), and the Rest of the World (the Middle East & Africa, and Latin America).

Technological advancements in diagnostics in the Asia-Pacific

The growth of the market in diagnostics is largely influenced by innovation in liver ultrasonography, serum biomarkers, MRI, and liquid biopsy for the detection and monitoring of early diseases. For instance, in July 2025, Apollo introduced an integrated clinic in Chennai, India, focused on advanced liver cancers and metastases. The clinic, India's first, integrates medical oncology, surgical gastroenterology, hepatobiliary surgery, radiation oncology, interventional radiology, medical genetics, pathology, anesthesia, pain, and palliative care to support Apollo's data collection, clinical research, and treatment innovation. Additionally, Tamil Nadu experienced an increase in HCC and liver metastases.

North America Maintains Strong Market Position

North America holds a significant share, owing to the market growth is primarily driven by the incidence of liver-related disorders on the rise, with a notable increase in cases of hepatitis infections, cirrhosis, nonalcoholic fatty liver disease, and alcohol-induced liver damage. These conditions are contributing to a higher prevalence of liver cancer, such as cholangiocarcinoma. This trend highlights the growing need for awareness and preventive measures to address liver health. According to the Cholangiocarcinoma Foundation Org., in 2024, cholangiocarcinoma is a cancer of the bile duct, a narrow tube that carries bile from the liver to the small intestine, interfering with food digestion.

Cholangiocarcinoma, being among the eight most lethal cancers, possesses a 5-year survival rate of approximately 20%, thus being a chronic and potentially life-threatening disease. Cholangiocarcinoma, a cancer of the liver and bile ducts, possesses a high fatality rate, with a projected 10,000 individuals suffering from it by the year 2040.

Similarly, as per the American Cancer Society Org., in 2025, cholangiocarcinoma, or bile duct cancer, is considered a rare disease. In the US, approximately 8,000 individuals receive a diagnosis each year, encompassing both types, such as intrahepatic (within the liver) and extrahepatic (outside the liver) bile duct cancers.

Market Players Outlook

The major companies operating in the global liver cancer treatment market include Bayer AG, Bristol-Myers Squibb Co., AstraZeneca, Eisai Inc., Exelixis, Inc., and F. Hoffmann-La Roche Ltd., among others. Market players are leveraging partnerships, collaborations, mergers, and acquisition strategies for business expansion and innovative Cancer Type development to maintain their market positioning.

Recent Developments

In June 2025, UPMC Central PA Surgical Oncology offered hepatic arterial infusion (HAI) pump therapy for patients with metastatic liver cancer or liver-related cancers. HAI therapy improves patient eligibility for surgery and overall survival by targeting tumors more precisely, reducing side effects, improving tumor response, and reducing tumor recurrence risk.
In March 2025, Central University of South Bihar (CUSB), along with IGIMS and NIPER, initiated research into the treatment of liver cancer through designer T-cells. An Indian Council of Medical Research grant of $0.116 million has been given to the project. The project aims to create new therapies and advance immunotherapies against liver cancer.
In November 2023, Terumo Corp. launched Occlusafe and LifePearl for the treatment of liver cancer. Hepatocellular carcinoma (HCC) is the most prevalent primary liver cancer, with more than 20,000 cases added every year in India. Embolization, like Transcatheter Arterial Chemo-Embolization (TACE), is a less invasive treatment. Occlusafe delivers chemotherapy medications more accurately and focuses on the tumor, with reduced harm to normal tissues. LifePearl facilitates the release of chemotherapeutic drugs at the tumor site, enhancing clinical efficacy.

The Report Covers:

Market value data analysis of 2025 and forecast to 2035.
Annualized market revenues ($ million) for each market segment.
Country-wise analysis of major geographical regions.
Key companies operating in the global hepatocellular carcinoma treatment market. Based on the availability of data, information related to new cancer types and relevant news is also available in the report.
Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
Analysis of market-entry and market expansion strategies.
Competitive strategies by identifying 'who-stands-where' in the market.

Product Code: OMR2023713

1. Report Summary

Current Industry Analysis and Growth Potential Outlook
Global Liver Cancer Treatment Market Sales Analysis - Cancer Type | Therapy Type ($ Million)
Liver Cancer Treatment Market Sales Performance of Top Countries
1.1. Research Methodology
Primary Research Approach
Secondary Research Approach
1.2. Market Snapshot

2. Market Overview and Insights

2.1. Scope of the Study
2.2. Analyst Insight & Current Market Trends
- 2.2.1. Key Liver Cancer Treatment Market Trends
- 2.2.2. Market Recommendations

3. Market Determinants

3.1. Market Drivers
- 3.1.1. Drivers For Global Liver Cancer Treatment Market: Impact Analysis
3.2. Market Pain Points and Challenges
- 3.2.1. Restraints For Global Liver Cancer Treatment Market: Impact Analysis
3.3. Market Opportunities
- 3.3.1. Opportunities For Global Liver Cancer Treatment Market: Impact Analysis

4. Competitive Landscape

4.1. Competitive Dashboard - Liver Cancer Treatment Market Revenue and Share by Manufacturers
Liver Cancer Treatment Comparison Analysis
Top Market Player Ranking Matrix
4.2. Key Company Analysis
- 4.2.1. Bayer AG
  - 4.2.1.1. Overview
  - 4.2.1.2. Product Portfolio
  - 4.2.1.3. Financial Analysis
  - 4.2.1.4. SWOT Analysis
  - 4.2.1.5. Business Strategy
- 4.2.2. Bristol-Myers Squibb Co.
  - 4.2.2.1. Overview
  - 4.2.2.2. Product Portfolio
  - 4.2.2.3. Financial Analysis
  - 4.2.2.4. SWOT Analysis
  - 4.2.2.5. Business Strategy
- 4.2.3. Eisai Inc.
  - 4.2.3.1. Overview
  - 4.2.3.2. Product Portfolio
  - 4.2.3.3. Financial Analysis
  - 4.2.3.4. SWOT Analysis
  - 4.2.3.5. Business Strategy
- 4.2.4. Exelixis, Inc.
  - 4.2.4.1. Overview
  - 4.2.4.2. Product Portfolio
  - 4.2.4.3. Financial Analysis
  - 4.2.4.4. SWOT Analysis
  - 4.2.4.5. Business Strategy
- 4.2.5. F. Hoffmann-La Roche Ltd.
  - 4.2.5.1. Overview
  - 4.2.5.2. Product Portfolio
  - 4.2.5.3. Financial Analysis
  - 4.2.5.4. SWOT Analysis
  - 4.2.5.5. Business Strategy
4.3. Top Winning Strategies by Market Players
- 4.3.1. Merger and Acquisition
- 4.3.2. Product Launch
- 4.3.3. Partnership And Collaboration

5. Global Liver Cancer Treatment Market Sales Analysis By Cancer Type ($ Million)

5.1. Hepatocellular Carcinoma (HCC)
5.2. Cholangiocarcinoma
5.3. Hepatoblastoma
5.4. Fibrolamellar Carcinoma
5.5. Others (Angiosarcoma of the Liver)

6. Global Liver Cancer Treatment Market Sales Analysis By Therapy Type ($ Million)

6.1. Targeted Therapy
6.2. Immunotherapy
6.3. Chemotherapy
6.4. Radiation Therapy
6.5. Surgical Interventions

7. Regional Analysis

7.1. North American Liver Cancer Treatment Market Sales Analysis - Cancer Type | Therapy Type ($ Million)
Macroeconomic Factors for North America
- 7.1.1. United States
- 7.1.2. Canada
7.2. European Liver Cancer Treatment Market Sales Analysis - Cancer Type | Therapy Type ($ Million)
Macroeconomic Factors for Europe
- 7.2.1. UK
- 7.2.2. Germany
- 7.2.3. Italy
- 7.2.4. Spain
- 7.2.5. France
- 7.2.6. Russia
- 7.2.7. Rest of Europe
7.3. Asia-Pacific Liver Cancer Treatment Market Sales Analysis - Cancer Type | Therapy Type ($ Million)
Macroeconomic Factors for Asia-Pacific
- 7.3.1. China
- 7.3.2. Japan
- 7.3.3. South Korea
- 7.3.4. India
- 7.3.5. Australia & New Zealand
- 7.3.6. ASEAN Countries (Thailand, Indonesia, Vietnam, Singapore, And Other)
- 7.3.7. Rest of Asia-Pacific
7.4. Rest of the World Liver Cancer Treatment Market Sales Analysis - Cancer Type | Therapy Type ($ Million)
Macroeconomic Factors for the Rest of the World
- 7.4.1. Latin America
- 7.4.2. Middle East and Africa

8. Company Profiles

8.1. AbbVie Inc.
- 8.1.1. Quick Facts
- 8.1.2. Company Overview
- 8.1.3. Product Portfolio
- 8.1.4. Business Strategies
8.2. AstraZeneca Plc
- 8.2.1. Quick Facts
- 8.2.2. Company Overview
- 8.2.3. Product Portfolio
- 8.2.4. Business Strategies
8.3. Bayer AG
- 8.3.1. Quick Facts
- 8.3.2. Company Overview
- 8.3.3. Product Portfolio
- 8.3.4. Business Strategies
8.4. BeiGene, Inc.
- 8.4.1. Quick Facts
- 8.4.2. Company Overview
- 8.4.3. Product Portfolio
- 8.4.4. Business Strategies
8.5. Boston Scientific Corp.
- 8.5.1. Quick Facts
- 8.5.2. Company Overview
- 8.5.3. Product Portfolio
- 8.5.4. Business Strategies
8.6. Bristol-Myers Squibb Co.
- 8.6.1. Quick Facts
- 8.6.2. Company Overview
- 8.6.3. Product Portfolio
- 8.6.4. Business Strategies
8.7. Eisai Inc.
- 8.7.1. Quick Facts
- 8.7.2. Company Overview
- 8.7.3. Product Portfolio
- 8.7.4. Business Strategies
8.8. Eli Lilly and Co.
- 8.8.1. Quick Facts
- 8.8.2. Company Overview
- 8.8.3. Product Portfolio
- 8.8.4. Business Strategies
8.9. Exelixis, Inc.
- 8.9.1. Quick Facts
- 8.9.2. Company Overview
- 8.9.3. Product Portfolio
- 8.9.4. Business Strategies
8.10. F. Hoffmann-La Roche Ltd.
- 8.10.1. Quick Facts
- 8.10.2. Company Overview
- 8.10.3. Product Portfolio
- 8.10.4. Business Strategies
8.11. Gilead Sciences, Inc.
- 8.11.1. Quick Facts
- 8.11.2. Company Overview
- 8.11.3. Product Portfolio
- 8.11.4. Business Strategies
8.12. Hepion Pharmaceuticals
- 8.12.1. Quick Facts
- 8.12.2. Company Overview
- 8.12.3. Product Portfolio
- 8.12.4. Business Strategies
8.13. Imunon
- 8.13.1. Quick Facts
- 8.13.2. Company Overview
- 8.13.3. Product Portfolio
- 8.13.4. Business Strategies
8.14. Johnson & Johnson Services, Inc.
- 8.14.1. Quick Facts
- 8.14.2. Company Overview
- 8.14.3. Product Portfolio
- 8.14.4. Business Strategies
8.15. Medtronic Ltd.
- 8.15.1. Quick Facts
- 8.15.2. Company Overview
- 8.15.3. Product Portfolio
- 8.15.4. Business Strategies
8.16. Merck & Co., Inc.
- 8.16.1. Quick Facts
- 8.16.2. Company Overview
- 8.16.3. Product Portfolio
- 8.16.4. Business Strategies
8.17. Novartis AG
- 8.17.1. Quick Facts
- 8.17.2. Company Overview
- 8.17.3. Product Portfolio
- 8.17.4. Business Strategies
8.18. Pfizer Inc.
- 8.18.1. Quick Facts
- 8.18.2. Company Overview
- 8.18.3. Product Portfolio
- 8.18.4. Business Strategies
8.19. Siemens Healthcare Pvt. Ltd.
- 8.19.1. Quick Facts
- 8.19.2. Company Overview
- 8.19.3. Product Portfolio
- 8.19.4. Business Strategies
8.20. Sirtex SIR-Spheres Pty Ltd.
- 8.20.1. Quick Facts
- 8.20.2. Company Overview
- 8.20.3. Product Portfolio
- 8.20.4. Business Strategies
8.21. Sumitomo Pharma Co., Ltd.
- 8.21.1. Quick Facts
- 8.21.2. Company Overview
- 8.21.3. Product Portfolio
- 8.21.4. Business Strategies
8.22. Terumo Corp.
- 8.22.1. Quick Facts
- 8.22.2. Company Overview
- 8.22.3. Product Portfolio
- 8.22.4. Business Strategies